Genentech Acquires Preclinical Cardiovascular Antibody In Nearly $200 Million Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm will make $15 million up-front payment to BioInvent for North American rights to BI-204.
You may also be interested in...
Roche To Partner With Two European Biotechs On Oncology Candidate
Deal with BioInvent International and ThromboGenics will develop the novel monoclonal antibody TB-403.
Roche To Partner With Two European Biotechs On Oncology Candidate
Deal with BioInvent International and ThromboGenics will develop the novel monoclonal antibody TB-403.
Genentech To Acquire AC Immune’s Beta-Amyloid Antibodies For Alzheimer’s Research
The biotech will pay more than $300 million for preclinical conformation-specific antibodies against beta-amyloid.